The particulars: oral semaglutide · 10 mg/mL · twelve weeks.
I would like to know whether this claim survives contact with evidence.
If the answer is "nobody has tested that", I would like that stated so I can stop looking.
Is this actually true, and what is the evidence?
twelve weeks is 84 days and, on a weekly schedule, 12 stopper punctures out of one vial at 10 mg/mL. Set the chemical question aside for a moment, because the puncture count is the one with a convention attached: 84 days is 3 times the twenty-eight days conventionally allowed for a preserved multi-dose preparation once it has been entered. Chemically, 10 mg/mL is high enough that adsorption to the glass is a rounding error and low enough that it is not protecting you from anything. What 12 withdrawals do add is 12 opportunities to introduce air, 12 coring events on the same stopper, and a headspace that grows with every draw — none of which show up on a certificate and all of which are avoided by splitting into aliquots at reconstitution.
The relevant point is that a mass shift of plus one dalton is deamidation and plus sixteen is oxidation, so degradation is often visible in a mass spectrum if anyone looks.
Light exposure matters for tryptophan-containing sequences and for anything with a chromophore. Amber vials and a closed box are free mitigations.
| Pathway | Dominant when | Detected by |
|---|---|---|
| Deamidation | Solution, neutral to alkaline pH | RP-HPLC, +1 Da on MS |
| Oxidation | Light, trace metals, peroxides | RP-HPLC, +16 Da on MS |
| Hydrolysis | Solution, extremes of pH | RP-HPLC, fragment masses |
| Aggregation | Agitation, interfaces, high concentration | SEC, visual haze; often invisible on RP-HPLC |
| Freeze-concentration damage | Freeze-thaw of buffered solution | SEC, loss of recovered content |
More usefully, freeze-thaw cycling drives aggregation through concentration at the ice interface and pH shifts as buffer components crystallise out at different rates. Each cycle costs something.
Aggregation at air-liquid interfaces is established from surface-tension and particle-count studies and is the basis for anti-agitation handling guidance.
At dilute concentrations, suspect adsorption before you suspect chemistry.
Analytical standards and reagents with traceable certificates. Every quantitative result you read inherits the accuracy of the standard behind it.
Shop standardsAnswering this needs the physical state, since a dry powder is protected from most of these and a solution is protected from none.
Deamidation converts asparagine or glutamine to the corresponding acid via a succinimide intermediate, adding one dalton. It is base-catalysed, accelerates above neutral pH and is the dominant aqueous pathway for many peptides.
Adsorption onto glass and plastic is significant at low concentrations — micrograms per millilitre — and negligible at milligrams per millilitre. It is the usual explanation for an apparent loss in a dilute preparation.
A mass spectrum names the pathway. Plus one, plus sixteen, minus eighteen.
The honest answer is that most reported "degradation" is adsorption and dilution error rather than chemistry.
A mass spectrum resolves most of this: minus eighteen is dehydration or succinimide, plus one is deamidation, plus sixteen is oxidation, and an unchanged mass with a shifted retention time is an isomer.
Stated carefully, oxidation targets methionine, cysteine and tryptophan, adding sixteen daltons per oxygen. It is catalysed by trace metals and promoted by dissolved oxygen and by light.
Adsorption losses at low concentrations are quantified in formulation studies and are the reason carrier proteins are used in dilute preparations.
Sequence decides which pathways are even available. Check the residues.
Start with the sequence, because which pathways are available depends on which residues are present.
Hydrolysis cleaves the backbone, most readily at aspartate-proline and aspartate-glycine sequences, and is acid-catalysed. In a dry solid it barely proceeds at all.
Deamidation via the succinimide intermediate is well characterised, with sequence-dependent rates highest for asparagine-glycine motifs.
Sequence determines which pathways apply, so general statements are general.
Swirl, never shake. Aggregation is a handling problem more than a time problem.
Answer first: the degradation pathways worth knowing are hydrolysis, deamidation, oxidation, aggregation and adsorption, and each has a different trigger and a different mitigation.
Aggregation is physical: peptides unfold at air-liquid interfaces and associate. Shaking maximises that interface, which is why swirling and shaking produce visibly different outcomes on the same vial.
Nothing here is medical advice, and research-use compounds are not approved for human use.
Cold, dry, dark, still. Those four words cover most of the mitigation.
edited 1 May 2025 by sian_llewellyn — added the citation requested in comments
Ask PeptideStack is a static archive. Posting is closed, but the norms are worth stating: answer the question that was asked, show your working, cite the trial or the certificate, and say plainly where the evidence runs out.